Oruka Therapeutics (ORKA) Other Working Capital Changes (2010 - 2024)
Oruka Therapeutics (ORKA) posted quarterly Other Working Capital Changes of -$125000.0 for Q1 2026, down 495.24% year-over-year from $31626.5 in Q1 2025, and down 725.0% quarter-over-quarter from $20000.0 in Q4 2025.
Analysis
Oruka Therapeutics (ORKA) Other Working Capital Changes (2010 - 2024) Analysis & Trends
Oruka Therapeutics' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$125000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 495.24% year-over-year to -$125000.0; the TTM figure through Mar 2026 stood at -$552000.0 (down 1183.72% YoY), while the FY2025 annual figure was -$448000.0, down 3100.0% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$125000.0, down from $20000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $2.4 million in Q3 2025, with the low at -$852000.0 in Q4 2024.
- The 5-year median for Other Working Capital Changes is $148000.0 (2025), against an average of $219882.4.
- Peak annual rise in Other Working Capital Changes reached 200.0% in 2025, while the deepest fall reached 22050.0% in 2025.
- Oruka Therapeutics' Other Working Capital Changes stood at -$20000.0 in 2024, then surged by 200.0% to $20000.0 in 2025, then plunged by 725.0% to -$125000.0 in 2026.
- Business Quant data shows ORKA's Other Working Capital Changes at -$125000.0 in Q1 2026, $20000.0 in Q4 2025, and -$439000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Oruka Therapeutics | 5.85 Bn | 4.12 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -230,000.00 |
| Jun 30, 2024 | -230,000.00 |
| Mar 31, 2024 | 606,000.00 |
| Mar 31, 2024 | 606,000.00 |
| Dec 31, 2023 | -238,000.00 |
| Dec 31, 2023 | -238,000.00 |
| Sep 30, 2023 | -200,000.00 |
| Sep 30, 2023 | -200,000.00 |
| Jun 30, 2023 | -253,000.00 |
| Jun 30, 2023 | -253,000.00 |
| Mar 31, 2023 | 598,000.00 |
| Mar 31, 2023 | 598,000.00 |
| Dec 31, 2022 | -357,000.00 |
| Dec 31, 2022 | -357,000.00 |
| Sep 30, 2022 | -607,000.00 |
| Sep 30, 2022 | -607,000.00 |
| Jun 30, 2022 | -258,000.00 |
| Jun 30, 2022 | -258,000.00 |
| Mar 31, 2022 | 414,000.00 |
| Mar 31, 2022 | 414,000.00 |